Coherus BioSciences, Inc.

NasdaqGM:CHRS Stock Report

Market Cap: US$244.0m

Coherus BioSciences Balance Sheet Health

Financial Health criteria checks 0/6

Coherus BioSciences has a total shareholder equity of $-193.4M and total debt of $473.4M, which brings its debt-to-equity ratio to -244.7%. Its total assets and total liabilities are $629.6M and $823.0M respectively.

Key information

-244.7%

Debt to equity ratio

US$473.37m

Debt

Interest coverage ration/a
CashUS$117.75m
Equity-US$193.42m
Total liabilitiesUS$823.03m
Total assetsUS$629.60m

Recent financial health updates

Recent updates

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13
The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul 06

Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Jun 15
Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Coherus: Will Its Chinese Gambit Fail?

May 27

Is Coherus BioSciences (NASDAQ:CHRS) Using Debt In A Risky Way?

Jan 06
Is Coherus BioSciences (NASDAQ:CHRS) Using Debt In A Risky Way?

Financial Position Analysis

Short Term Liabilities: CHRS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CHRS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CHRS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CHRS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CHRS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CHRS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.5% each year


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.